Methylomic signature of current cannabis use in two first-episode psychosis cohorts.

Journal

Molecular psychiatry

ISSN: 1476-5578

Titre abrégé: Mol Psychiatry

Pays: England

ID NLM: 9607835

Informations de publication

Date de publication:
16 Oct 2024

Historique:

received: 17 08 2023

accepted: 31 07 2024

revised: 24 07 2024

medline: 16 10 2024

pubmed: 16 10 2024

entrez: 15 10 2024

Statut: aheadofprint

Résumé

The rising prevalence and legalisation of cannabis worldwide have underscored the need for a comprehensive understanding of its biological impact, particularly on mental health. Epigenetic mechanisms, specifically DNA methylation, have gained increasing recognition as vital factors in the interplay between risk factors and mental health. This study aimed to explore the effects of current cannabis use and high-potency cannabis on DNA methylation in two independent cohorts of individuals experiencing first-episode psychosis (FEP) compared to control subjects. The combined sample consisted of 682 participants (188 current cannabis users and 494 never users). DNA methylation profiles were generated on blood-derived DNA samples using the Illumina DNA methylation array platform. A meta-analysis across cohorts identified one CpG site (cg11669285) in the CAVIN1 gene that showed differential methylation with current cannabis use, surpassing the array-wide significance threshold, and independent of the tobacco-related epigenetic signature. Furthermore, a CpG site localised in the MCU gene (cg11669285) achieved array-wide significance in an analysis of the effect of high-potency (THC = > 10%) current cannabis use. Pathway and regional analyses identified cannabis-related epigenetic variation proximal to genes linked to immune and mitochondrial function, both of which are known to be influenced by cannabinoids. Interestingly, a model including an interaction term between cannabis use and FEP status identified two sites that were significantly associated with current cannabis use with a nominally significant interaction suggesting that FEP status might moderate how cannabis use affects DNA methylation. Overall, these findings contribute to our understanding of the epigenetic impact of current cannabis use and highlight potential molecular pathways affected by cannabis exposure.

Identifiants

DOI: 10.1038/s41380-024-02689-0 PMID: 39406996

pubmed: 39406996

doi: 10.1038/s41380-024-02689-0

pii: 10.1038/s41380-024-02689-0

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7:16.

pubmed: 33627670 pmcid: 8655458 doi: 10.1038/s41572-021-00247-4

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42:1262–9.

pubmed: 26884547 pmcid: 4988731 doi: 10.1093/schbul/sbw003

Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371:879.

pubmed: 25162899

Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2018;23:1287–92.

pubmed: 28115737 doi: 10.1038/mp.2016.252

Johnson EC, Hatoum AS, Deak JD, Polimanti R, Murray RM, Edenberg HJ, et al. The relationship between cannabis and schizophrenia: a genetically informed perspective. Addiction. 2021;116:3227–34.

pubmed: 33950550 pmcid: 8492483 doi: 10.1111/add.15534

Gillespie NA, Kendler KS. Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry. 2021;78:467–8.

pubmed: 33146687 doi: 10.1001/jamapsychiatry.2020.3564

Hjorthoj C, Posselt CM, Nordentoft M. Development over time of the population-attributable risk fraction for cannabis use disorder in schizophrenia in Denmark. JAMA Psychiatry. 2021;78:1013–9.

pubmed: 34287621 doi: 10.1001/jamapsychiatry.2021.1471

Goncalves-Pinho M, Braganca M, Freitas A. Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. Int J Methods Psychiatr Res. 2020;29:e1813.

pubmed: 31808250 doi: 10.1002/mpr.1813

Jin Z, Liu Y. DNA methylation in human diseases. Genes Dis. 2018;5:1–8.

pubmed: 30258928 pmcid: 6147084 doi: 10.1016/j.gendis.2018.01.002

Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS ONE. 2013;8:e63812.

pubmed: 23691101 pmcid: 3656907 doi: 10.1371/journal.pone.0063812

Shenker NS, Polidoro S, van Veldhoven K, Sacerdote C, Ricceri F, Birrell MA, et al. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet. 2013;22:843–51.

pubmed: 23175441 doi: 10.1093/hmg/dds488

Tsaprouni LG, Yang TP, Bell J, Dick KJ, Kanoni S, Nisbet J, et al. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics. 2014;9:1382–96.

pubmed: 25424692 pmcid: 4623553 doi: 10.4161/15592294.2014.969637

Markunas CA, Hancock DB, Xu Z, Quach BC, Fang F, Sandler DP, et al. Epigenome-wide analysis uncovers a blood-based DNA methylation biomarker of lifetime cannabis use. Am J Med Genet Part B, Neuropsychiatr Genet. 2021;186:173–82.

doi: 10.1002/ajmg.b.32813

Osborne AJ, Pearson JF, Noble AJ, Gemmell NJ, Horwood LJ, Boden JM, et al. Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort. Transl Psychiatry. 2020;10:114.

pubmed: 32321915 pmcid: 7176736 doi: 10.1038/s41398-020-0800-3

Alpar A, Tortoriello G, Calvigioni D, Niphakis MJ, Milenkovic I, Bakker J, et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. Nat Commun. 2014;5:4421.

pubmed: 25030704 doi: 10.1038/ncomms5421

Clark SL, Chan R, Zhao M, Xie LY, Copeland WE, Aberg KA, et al. Methylomic investigation of problematic adolescent cannabis use and its negative mental health consequences. J Am Acad Child Adolesc Psychiatry. 2021;60:1524–32.

pubmed: 33631312 pmcid: 8380262 doi: 10.1016/j.jaac.2021.02.008

Gerra MC, Jayanthi S, Manfredini M, Walther D, Schroeder J, Phillips KA, et al. Gene variants and educational attainment in cannabis use: mediating role of DNA methylation. Transl Psychiatry. 2018;8:23.

pubmed: 29353877 pmcid: 5802451 doi: 10.1038/s41398-017-0087-1

Grzywacz A, Barczak W, Chmielowiec J, Chmielowiec K, Suchanecka A, Trybek G, et al. Contribution of dopamine transporter gene methylation status to cannabis dependency. Brain Sci. 2020;10:400.

van der Knaap LJ, Schaefer JM, Franken IH, Verhulst FC, van Oort FV, Riese H. Catechol-O-methyltransferase gene methylation and substance use in adolescents: the TRAILS study. Genes, Brain Behavior. 2014;13:618–25.

pubmed: 24902721 doi: 10.1111/gbb.12147

Tao R, Li C, Jaffe AE, Shin JH, Deep-Soboslay A, Yamin R, et al. Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl Psychiatry. 2020;10:158.

pubmed: 32433545 pmcid: 7237456 doi: 10.1038/s41398-020-0832-8

Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.

pubmed: 17828291 doi: 10.1038/sj.bjp.0707442

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Rev Genet. 2018;19:371–84.

pubmed: 29643443 doi: 10.1038/s41576-018-0004-3

Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks MP. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. Ageing Res Rev. 2021;69:101348.

pubmed: 33930583 doi: 10.1016/j.arr.2021.101348

Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high-potency cannabis: a case-control study. Lancet Psychiatry. 2015;2:233–8.

pubmed: 26359901 doi: 10.1016/S2215-0366(14)00117-5

Gayer-Anderson C, Jongsma HE, Di Forti M, Quattrone D, Velthorst E, de Haan L, et al. The European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI): incidence and first-episode case-control programme. Soc Psychiatry Psychiatr Epidemiol. 2020;55:645–57.

pubmed: 31974809 doi: 10.1007/s00127-020-01831-x

Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.

pubmed: 30902669 pmcid: 7646282 doi: 10.1016/S2215-0366(19)30048-3

Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98:288–95.

pubmed: 21839163 doi: 10.1016/j.ygeno.2011.07.007

Alameda L, Liu Z, Sham PC, Aas M, Trotta G, Rodriguez V, et al. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis-findings from the EU-GEI study. Mol Psychiatry 2023;28:2095–106.

Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genom. 2013;14:293.

doi: 10.1186/1471-2164-14-293

Hannon E, Dempster EL, Mansell G, Burrage J, Bass N, Bohlken MM, et al. DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. eLife. 2021;10:e58430.

pubmed: 33646943 pmcid: 8009672 doi: 10.7554/eLife.58430

Ekstrom C, Dalgaard P, Gill J, Weibelzahl S, Anandkumar A, Ford C, et al. pwr: Basic functions for power analysis. 2017 https://cran.r-project.org/web/packages/pwr/ .

R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, 2022.

Houseman EA, Kile ML, Christiani DC, Ince TA, Kelsey KT, Marsit CJ. Reference-free deconvolution of DNA methylation data and mediation by cell composition effects. BMC Bioinform. 2016;17:259.

doi: 10.1186/s12859-016-1140-4

Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. Differences in smoking associated DNA methylation patterns in South Asians and Europeans. Clin Epigenetics. 2014;6:4.

pubmed: 24485148 pmcid: 3915234 doi: 10.1186/1868-7083-6-4

Möbius T. Metagen: inference in meta-analysis and meta regression. R Package Version 2014; 1.

Saffari A, Silver MJ, Zavattari P, Moi L, Columbano A, Meaburn EL, et al. Estimation of a significance threshold for epigenome-wide association studies. Genet Epidemiol. 2018;42:20–33.

pubmed: 29034560 doi: 10.1002/gepi.22086

Ren X, Kuan PF. methylGSA: a Bioconductor package and Shiny app for DNA methylation data length bias adjustment in gene set testing. Bioinformatics. 2019;35:1958–9.

pubmed: 30346483 doi: 10.1093/bioinformatics/bty892

Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P values. Bioinformatics. 2012;28:2986–8.

pubmed: 22954632 pmcid: 3496335 doi: 10.1093/bioinformatics/bts545

Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:3156.

doi: 10.1186/gb-2013-14-10-r115

Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49:359–67.

pubmed: 23177740 doi: 10.1016/j.molcel.2012.10.016

Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10:573–91.

pubmed: 29676998 pmcid: 5940111 doi: 10.18632/aging.101414

Belsky DW, Caspi A, Corcoran DL, Sugden K, Poulton R, Arseneault L, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.

pubmed: 35029144 pmcid: 8853656 doi: 10.7554/eLife.73420

Pacault M, Nizon M, Pichon O, Vincent M, Le Caignec C, Isidor B. A de novo 2q37.2 deletion encompassing AGAP1 and SH3BP4 in a patient with autism and intellectual disability. Eur J Med Genet. 2019;62:103586.

pubmed: 30472483 doi: 10.1016/j.ejmg.2018.11.020

Garg P, Sharp AJ. Screening for rare epigenetic variations in autism and schizophrenia. Hum Mutat. 2019;40:952–61.

pubmed: 30900359 pmcid: 6801017

Jiang Y, Krantz S, Qin X, Li S, Gunasekara H, Kim YM, et al. Caveolin-1 controls mitochondrial damage and ROS production by regulating fission-fusion dynamics and mitophagy. Redox Biol. 2022;52:102304.

pubmed: 35413643 pmcid: 9018165 doi: 10.1016/j.redox.2022.102304

Yi K, Cui X, Liu X, Wang Y, Zhao J, Yang S, et al. PTRF/Cavin-1 as a Novel RNA-binding protein expedites the NF-κB/PD-L1 axis by stabilizing lncRNA NEAT1, Contributing to tumorigenesis and immune evasion in glioblastoma. Front Immunol. 2021;12:802795.

pubmed: 35069587 doi: 10.3389/fimmu.2021.802795

Serrat R, Covelo A, Kouskoff V, Delcasso S, Ruiz-Calvo A, Chenouard N, et al. Astroglial ER-mitochondria calcium transfer mediates endocannabinoid-dependent synaptic integration. Cell Rep. 2021;37:110133.

pubmed: 34936875 doi: 10.1016/j.celrep.2021.110133

Sun X, Johnson J, St, John JC. Global DNA methylation synergistically regulates the nuclear and mitochondrial genomes in glioblastoma cells. Nucleic Acids Res. 2018;46:5977–95.

pubmed: 29722878 pmcid: 6158714 doi: 10.1093/nar/gky339

Guennewig B, Bitar M, Obiorah I, Hanks J, O’Brien EA, Kaczorowski DC, et al. THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018;8:89.

pubmed: 29691375 pmcid: 5915454 doi: 10.1038/s41398-018-0137-3

Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19:833.

Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, et al. Mitochondrial CB

pubmed: 22388959 doi: 10.1038/nn.3053

Mendizabal-Zubiaga J, Melser S, Benard G, Ramos A, Reguero L, Arrabal S, et al. Cannabinoid CB(1) receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration. Front Physiol. 2016;7:476.

pubmed: 27826249 pmcid: 5078489 doi: 10.3389/fphys.2016.00476

Olivas-Aguirre M, Torres-Lopez L, Valle-Reyes JS, Hernandez-Cruz A, Pottosin I, Dobrovinskaya O. Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia. Cell Death Dis. 2019;10:779.

pubmed: 31611561 pmcid: 6791884 doi: 10.1038/s41419-019-2024-0

Jimenez-Blasco D, Busquets-Garcia A, Hebert-Chatelain E, Serrat R, Vicente-Gutierrez C, Ioannidou C, et al. Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature. 2020;583:603–8.

pubmed: 32641832 doi: 10.1038/s41586-020-2470-y

Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, Busquets-Garcia A, et al. A cannabinoid link between mitochondria and memory. Nature. 2016;539:555–9.

pubmed: 27828947 doi: 10.1038/nature20127

Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M. Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci Biobehav Rev. 2015;48:10–21.

pubmed: 25446950 doi: 10.1016/j.neubiorev.2014.11.005

Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020;7:1032–45.

pubmed: 33096046 pmcid: 7674631 doi: 10.1016/S2215-0366(20)30339-4

Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333–49.

pubmed: 20191092 doi: 10.4155/fmc.09.93

Khoury M, Cohen I, Bar-Sela G. “The two sides of the same coin”-Medical cannabis, cannabinoids and immunity: pros and cons explained. Pharmaceutics 2022;14:389.

Allen JP, Danoff JS, Costello MA, Hunt GL, Hellwig AF, Krol KM, et al. Lifetime marijuana use and epigenetic age acceleration: A 17-year prospective examination. Drug Alcohol Depend. 2022;233:109363.

pubmed: 35231715 pmcid: 8982677 doi: 10.1016/j.drugalcdep.2022.109363

Klopack ET, Carroll JE, Cole SW, Seeman TE, Crimmins EM. Lifetime exposure to smoking, epigenetic aging, and morbidity and mortality in older adults. Clin Epigenetics. 2022;14:72.

pubmed: 35643537 pmcid: 9148451 doi: 10.1186/s13148-022-01286-8

Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. 2008;53:90–4.

pubmed: 18279244 doi: 10.1111/j.1556-4029.2007.00603.x

Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction. 2014;109:1686–94.

pubmed: 24894801 doi: 10.1111/add.12634

Zamengo L, Frison G, Bettin C, Sciarrone R. Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal. 2015;7:255–8.

pubmed: 25069834 doi: 10.1002/dta.1690

Niesink RJ, Rigter S, Koeter MW, Brunt TM. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction. 2015;110:1941–50.

pubmed: 26234170 doi: 10.1111/add.13082

Oliveira GLD, Voloch MH, Sztulman GB, Neto ON, Yonamine M. Cannabinoid contents in cannabis products seized in São Paulo, Brazil, 2006–2007. Forensic Toxicol. 2008;26:31–5.

doi: 10.1007/s11419-008-0046-x

Hardwick S Home Office Cannabis Potency Study 2008. In: office H (ed). Home Office Scientific Development Branch: Home Office Scientific Development Branch, 2008.

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. 2016, 2016.

Reitox National Focal Point. 2012 NATIONAL REPORT (2011 data) TO THE EMCDDA by the Reitox National Focal Point SPAIN: New Development, Trends and in-depth information on selected issues. 2012.

R N. THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2012–2013). 2013.

Brisacier AC. Observatoire Français Des Drogues et Des Toxicomanies (OFDT). Drugs, Key Data 6th edition 2015.

Smith AK, Ratanatharathorn A, Maihofer AX, Naviaux RK, Aiello AE, Amstadter AB, et al. Epigenome-wide meta-analysis of PTSD across 10 military and civilian cohorts identifies methylation changes in AHRR. Nat Commun. 2020;11:5965.

pubmed: 33235198 pmcid: 7686485 doi: 10.1038/s41467-020-19615-x

McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nature Biotechnol. 2010;28:495–501.

doi: 10.1038/nbt.1630